The Fabrication And Evaluation of the Formulation Variables of a Controlled-Porosity Osmotic Drug Delivery System with Diltiazem Hydrochloride

Pundarikakshudu,Kilambi;

The Fabrication And Evaluation of the Formulation Variables of a Controlled-Porosity Osmotic Drug Delivery System with Diltiazem Hydrochloride

September 2, 2003

By Kilambi Pundarikakshudu, PhD

Publication

Article

Pharmaceutical TechnologyPharmaceutical Technology-09-02-2003

Volume 27

Issue 9

The study presented in this article used a controlled-porosity osmotic pump, which was prepared in the form of a bilayered tablet containing a drug compartment and an osmogen layer for the delayed release of diltiazem HCI.

External Link - article-70094.pdf

Articles in this issue

September 2003

In the Spotlight September 2003

Counterfeiting, Compliance, and Controls

September 2003

The Fabrication And Evaluation of the Formulation Variables of a Controlled-Porosity Osmotic Drug Delivery System with Diltiazem Hydrochloride

Disposable Filtration Lightens Cleaning and Validation Load

CROs Hoping for Research Burst in Second Half of 2003

Positron Emission Particle Tracking Studies of a Wurster Process for Coating Applications

Improved Blister Packaging Benefits Consumers, Caregivers, and Drug Makers

Related Content

Movement towards the intended goal. Moving forward, step by step. Labor and aspiration. Motivation, self-development. Business strategic planning, risk management. New opportunities. Achieve. | Image Credit: ©Andrii Yalanskyi – Stock.Adobe.com

Steps to Process Development Optimization

Susan Haigney

February 4th 2025

Article

The optimization of processes for the development and manufacture of biopharmaceuticals is pivotal for producing quality products.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

3d rendering of Antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells | Image Credit: © Love Employee - © Love Employee- stock.adobe.com

Advancing ADCs to the Next Level

Feliza Mirasol

February 4th 2025

Article

CDMOs who have integrated technologies can help further the advancement of ADC development.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024

Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.